来自官方财务报表的收入、利润与现金流历史。
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
| 利润表 | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| 毛利 | — | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | $0M | — | — | — |
| 毛利率% | — | — | — | — | — | — | — | — | — | — | — |
| 营业利润（EBIT） | ($559M) | ($533M) | ($438M) | ($270M) | ($208M) | ($156M) | ($108M) | ($60M) | $0M | $0M | ($137M) |
| 营业利润率% | -7877.5% | — | — | — | — | — | — | — | — | — | — |
| 净利 | ($538M) | ($506M) | ($414M) | ($259M) | ($211M) | ($157M) | ($107M) | ($66M) | $0M | $0M | ($137M) |
| 净利润率 % | -7585.9% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($539M) | ($505M) | ($413M) | ($259M) | ($198M) | ($157M) | ($108M) | ($66M) | $0M | — | — |
| 每股收益（EPS） | $-2.81 | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-0.00 | — | $-13.67 |
| 已发行股数 (M) | 206M | 182M | 152M | 138M | 123M | 110M | 88M | 43M | 14M | — | 10M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 IMVT 交互式查看器。 /companies/us/IMVT
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms